1. Home
  2. Clinical Topics
  3. FDA approves marketing of postnatal test for developmental disabilities
Clinical TopicsDrugs and DevicesHealthcare & TechnologyNewsPediatricsWeb Exclusives

FDA approves marketing of postnatal test for developmental disabilities

Share

On Jan. 17, the U.S. Food and Drug Administration (FDA) announce that it has authorized for marketing the Affymetrix CytoScan Dx Assay, which can detect chromosomal variations that may be responsible for a child’s developmental delay or intellectual disability. Read more.

Leave a Reply

Your email address will not be published.

Fill out this field
Fill out this field
Please enter a valid email address.

Get your free subscription to NurseLine!

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Recent Posts